Agents with efficacy in HER2 – low metastatic breast cancer, include trastuzumab-deruxtecan an ADC agent, and Sacituzumab govitecan also an ADC agent.
Categories
Standard of CareStandard of CareAgents with efficacy in HER2 – low metastatic breast cancer, include trastuzumab-deruxtecan an ADC agent, and Sacituzumab govitecan also an ADC agent.